Complete PET/CT extinction and subsequent risk of aortic dilation in patients with giant cell arteritis-related large vessel vasculitis treated with tocilizumab
This study suggests that TCZ is an interesting therapeutic option for achieving complete metabolic response on PET/CT in patients with GCA-related LVV. The subsequent risk of aortic dilation may be reduced.
Authors
- E. Berthoux
- Olivier Espitia (ORCID: https://orcid.org/0000-0003-0821-9990)
- C. Delacotte
- Samuel Deshayes (ORCID: https://orcid.org/0000-0001-8887-3233)
- Sophie Gallou (ORCID: https://orcid.org/0000-0002-9915-8451)
- L. Sailler (ORCID: https://orcid.org/0000-0003-3482-6903)
- Martin Morard (ORCID: https://orcid.org/0000-0002-0518-9557)
- Rémi Philip (ORCID: https://orcid.org/0000-0003-0797-9170)
- Chloé Comarmond-Ortoli
- Jean‐François Alexandra
- Nicolas Martin-Silva
- Jonathan Boutémy
- A. Dumont
- Maxime Samson
- Achille Aouba
- Gwénola Maigné
- Hubert de Boysson
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université de Bourgogne (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Université Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Normandie Université (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Hôpital Lariboisière (FR)
- Institut du Thorax (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Centre Hospitalier Saint-Joseph Saint-Luc (FR)
- Université Bourgogne Europe (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- RMD Open
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-006563
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00